Accueil   Diary - News   All news ElsaLys Biotech raising 2,7 M€

ElsaLys Biotech raising 2,7 M€

ElsaLys Biotech announces the completion of the first instalment of a total fundraising amounting to € 5 million

 

IM Europe and Sofimac Partners are the main investors

 

 

ElsaLys Biotech, a biopharmaceutical company dedicated to the development of "best-in-disease" therapeutic antibodies for oncology and ophthalmology, announces today that it has completed the first instalment of a € 5 million fundraising.


This first instalment of € 2.7 million was subscribed by Sofimac Partners, already a shareholder, and by IM Europe, a subsidiary of Institut Mérieux and Crédit Agricole Création.

 

 

Read the press release